Larson Financial Group LLC Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Larson Financial Group LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 6,016.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,468 shares of the medical research company’s stock after purchasing an additional 1,444 shares during the quarter. Larson Financial Group LLC’s holdings in Edwards Lifesciences were worth $136,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Allspring Global Investments Holdings LLC lifted its holdings in shares of Edwards Lifesciences by 4.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock valued at $31,603,000 after purchasing an additional 14,087 shares during the last quarter. Empowered Funds LLC boosted its holdings in Edwards Lifesciences by 151.2% in the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after acquiring an additional 12,112 shares in the last quarter. Cetera Advisors LLC grew its stake in shares of Edwards Lifesciences by 175.1% during the first quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after acquiring an additional 24,242 shares during the last quarter. TD Asset Management Inc grew its stake in shares of Edwards Lifesciences by 95.1% during the fourth quarter. TD Asset Management Inc now owns 1,323,611 shares of the medical research company’s stock worth $100,925,000 after acquiring an additional 645,204 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Edwards Lifesciences by 10.8% during the fourth quarter. Sei Investments Co. now owns 558,031 shares of the medical research company’s stock valued at $42,550,000 after acquiring an additional 54,595 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. TD Cowen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Stifel Nicolaus cut their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Canaccord Genuity Group lowered their price target on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. The Goldman Sachs Group cut their price objective on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Finally, JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $105.00 to $72.00 in a report on Thursday, July 25th. Fourteen investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $82.10.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock valued at $1,321,988 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $66.81 on Friday. The stock has a market capitalization of $40.26 billion, a price-to-earnings ratio of 28.80, a PEG ratio of 2.92 and a beta of 1.11. The stock has a 50-day moving average of $74.75 and a 200 day moving average of $84.15. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the prior year, the company posted $0.66 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.